1-trityl-3-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]-4-methyl-1H-imidazol-3-ium

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-trityl-3-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]-4-methyl-1H-imidazol-3-ium
• 英文别名: 2-[3-(5-Methyl-3-tritylimidazol-3-ium-1-yl)propyl]isoindole-1,3-dione
• 化学式: C₃₄H₃₀N₃O₂
• 分子量: 512.631
• InChiKey: PCVXSOSWXJBFGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲基咪唑 、 N-(3-溴丙基)苯二胺 、 三苯基氯甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 、 二氯甲烷 为溶剂， 反应 11.67h， 以15.1%的产率得到2-(3-(4-methyl-1H-imidazol-1-yl)propyl)isoindoline-1,3-dione
  参考文献：
  名称：

  Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement

  摘要：

  The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of A beta(3,11(pE)-40,42), as these A beta-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of A beta-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of A beta(3,11(pE)-40,42) formation.

  DOI：

  10.1021/jm900969p

文献信息

• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Buchholz Mirko

  公开号：US20080267911A1

  公开（公告）日：2008-10-30

  Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R 1 represents and R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 , X 4 , Y and Z are as defined throughout the description and the claims.

  式(I)的化合物，其组合物及用途用于疾病治疗，或其药学上可接受的盐、溶剂化合物或多晶形式，包括其所有互变异构体和立体异构体，其中： R1代表，而R2、R3、R4、R5、R6、X1、X2、X3、X4、Y和Z如描述和权利要求中所定义。
• Thiourea derivatives as glutaminyl cyclase inhibitors
  申请人：Probiodrug AG

  公开号：EP2865670A1

  公开（公告）日：2015-04-29

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.

  本发明涉及用于疾病治疗的式 (I) 化合物、其组合物和用途、 或其药学上可接受的盐、溶液或多晶型，包括其所有同系物和立体异构体 其中 A 代表 和 B、R1、R2、R3、R4、R5、R6 和 Z 在整个描述和权利要求中的定义。
• THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS
  申请人：Probiodrug AG

  公开号：EP2142514B1

  公开（公告）日：2014-12-24
• US8188094B2
  申请人：——

  公开号：US8188094B2

  公开（公告）日：2012-05-29
• US8227498B2
  申请人：——

  公开号：US8227498B2

  公开（公告）日：2012-07-24